Prognosis of IgA Nephropathy with Stages 3b-5 CKD
Kidney and Blood Pressure Research · 2024
DOI: 10.1159/000538506 ↗Kurz gefasst
Fachartikel in der Zeitschrift Kidney and Blood Pressure Research, 2024. Verfasst von Zhanfei Wu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Tianjin Medical University General Hospital, Tianjin, China. Hauptthemen laut MEDLINE: Glomerulonephritis, IGA, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
There are conflicting opinions regarding the use of immunosuppressant treatment in IgA nephropathy (IgAN) patients with an estimated glomerular filtration rate (eGFR) of less than 45 mL/min/1.73 m2 and persistent proteinuria with a daily excretion of ≥1.0 g.
Methods
This retrospective study involved 110 IgAN patients for whom clinical data were available; of these, 90 had complete follow-up data. Patients were grouped based on whether they received immunotherapy during follow-up, their renal function, proteinuria levels, and the percentage of crescentic glomeruli observed at the time of renal biopsy.
Results
The mean eGFR for the participants was 32.0 ± 10.2 mL/min/1.73 m2. The average follow-up duration was 46.1 ± 37.9 months. The mean rate of decline in eGFR was 3.6 mL/min/1.73 m2 per year. There were 43 (47.8%) composite kidney endpoints occurred in these patients. In the group that received immunotherapy, the incidence of kidney endpoint events was lower than in the untreated group (45.1% vs. 57.9%), but the difference was not statistically significant (p = 0.320). Among patients with stage CKD 3b, the incidence of endpoint events was lower than in those with stages CKD 4 and 5 (36.8% vs. 66.7%, p = 0.006). Conversely, the high proteinuria group saw a higher incidence of endpoint events compared to the low proteinuria group (51.9% vs. 23.1%), although this difference was not statistically significant (p = 0.054). Meanwhile, there was no significant difference in the incidence of endpoint events between the two crescent glomerular ratio groups (48.7% vs. 41.7%, p = 0.649). Kaplan-Meier survival analysis indicated that renal function level (p < 0.001) and proteinuria (p = 0.023) were associated with renal survival in IgAN patients. In contrast, the administration of immunosuppressive therapy (p = 0.288) and the prevalence of C lesions (p = 0.982) did not show a significant association with renal survival. Further, Cox regression analysis identified systolic blood pressure, fibrinogen, and CKD stage as risk factors for eGFR decline in IgAN patients (all p < 0.05).
Conclusion
IgAN patients with stages 3b-5 CKD exhibited a poor prognosis. It appears that in this specific cohort of IgAN patients, immunosuppressive therapy may not provide significant advantages over supportive care therapeutic regimens in terms of disease management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, Tianjin Medical University General Hospital, Tianjin, China.
- Department of Nephrology, Tianjin Medical University General Hospital, Tianjin, China, 5liuyouxia@163.com.
- Department of Nephrology, Tianjin Medical University General Hospital, Tianjin, China, jiajunya@126.com.
Zitieren
APA
Wu, Z., Li, H., Liu, Y., Wang, F., Xing, Y., Li, W., Jia, J., & Yan, T. (2024). Prognosis of IgA Nephropathy with Stages 3b-5 CKD. Kidney and Blood Pressure Research. https://doi.org/10.1159/000538506
Vancouver
Wu Z, Li H, Liu Y, Wang F, Xing Y, Li W, et al. Prognosis of IgA Nephropathy with Stages 3b-5 CKD. Kidney and Blood Pressure Research. 2024. doi:10.1159/000538506
BibTeX
@article{Wu2024,
author = {Wu, Zhanfei and Li, Hongfen and Liu, Youxia and Wang, Fanghao and Xing, Yue and Li, Wenying and Jia, Junya and Yan, Tiekun},
title = {Prognosis of IgA Nephropathy with Stages 3b-5 CKD},
journal = {Kidney and Blood Pressure Research},
year = {2024},
doi = {10.1159/000538506}
}
EUVIMED